Isofol Medical

Isofol is a clinical stage pharmaceutical company developing novel products for unmet needs within oncology. Isofol’s lead clinical candidate, Modufolin®, is predicted to improve the outlook for cancer patients undergoing chemotherapy treatment with a range of antimetabolites. Isofol’s ongoing clinical trials are focusing on colorectal cancer and osteosarcoma. Isofol collaborates closely with its strategic R&D partner Merck Millipore, the world’s leading manufacturer of reduced folates.

Full Story >

stor orange

Modufolin® development

Modufolin® is a folate-based bio-modulator designed to replace leucovorin/levoleucovorin as the preferred treatment to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-FU (5-flluorouracil). It is currently being evaluated in three Phase I/II studies, two in colorectal cancer and one in osteosarcoma.
Although several modern chemo drugs have been introduced that dramatically improve the treatment of many cancer diseases, they show limited effect in treating solid tumors. 5-FU and leucovorin/levoleucovorin is still the core treatment used today for colorectal cancer and Modufolin® has the potential to enable 5-FU to work more effectively.

Read more about Modufolin

Stay informed

Click the link below to stay informed about our progress.

Clinical trials

To find out the latest news about our ongoing clinical phase II trial please go to:

Development pipeline

Click the link below to find out more about our development pipeline:

News & Press information

First patient enrolled in Isofol Medical’s Phase I/II trial of Modufolin® in combination with 5‐FU and oxaliplatin in patients with stage IV colon cancer.
10/30/2014: Isofol Medical AB today announced that the first patient has been enrolled in a Phase I/II, single centre, open label study to identify the safety and tolerability of a dose range of Modufolin in combination with the routine doses of 5-­‐FU and oxaliplatin. The study, ISO-­‐CC-­‐ 005 (NCT02244632), will be carried out in patients with stage IV colon cancer and the results will be used to define the dose to be further documented in a blinded multicentre efficacy trial.
Recipharm forms new collaboration with Isofol Medical to exclusively manufacture Modufolin® and invests SEK 8 million in the company
8/26/2014: Recipharm and Isofol Medical AB, a Gothenburg-based pharmaceutical company developing novel products for unmet needs within oncology, are pleased to announce the formation of a collaboration to strengthen the development program of Isofol’s lead drug candidate Modufolin®.
Isofol Medical AB, Biotech Center, Arvid Wallgrens Backe 20, SE-413 46 Gothenburg, Sweden
Phone: +46 (0) 707 64 65 00 E-mail: